Lymphoma
Conditions
Keywords
extranodal marginal zone lymphoma, ocular adnexal lymphoma, mucosa associated lymphoid tissue, cyclophosphamide, vincristine, prednisolone
Brief summary
The purpose of this study is to determine how efficient the combination of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) is in the treatment of stage I or II non-conjunctival ocular adnexal MALT lymphoma (OAML).
Detailed description
The treatment of stage I or II OAML is mainly composed of radiotherapy because chemotherapy including cyclophosphamide, vincristine, and prednisolone (CVP) did not show the acceptable response rate compared with radiotherapy. However, radiotherapy for this disease can cause many complications of eyes. This clinical trial was designed to examine the efficacy of R-CVP combination therapy as a first-line treatment for stage I or II non-conjunctival OAML aiming to avoid radiation hazard and increase the efficacy of CVP chemotherapy.
Interventions
DRUGrituximab, cyclophosphamide, vincristine, and prednisolone
6 cycles of R-CVP followed by 2 cycles of rituximab
Sponsors
Seoul St. Mary's Hospital
Konkuk University Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed OAML * Non-conjunctival or bilateral conjunctival (TNM-based, above T1N0M0 or bT1N0M0), Ann Arbor stage I and II OAML * Previously untreated * Age ≥18 years * Performance status: ECOG 0-2 * Adequate hematological function: hemoglobin ≥9 g/dL,, absolute neutrophil count (ANC) ≥1,500/μL, and platelet count ≥100,000/μL, unless abnormalities are due to bone marrow involvement by the lymphoma * Adequate liver function tests: i. Transaminase (AST/ALT) \<3 times the upper normal value ii. Bilirubin \<2 times the upper normal value * Adequate renal function:serum creatinine level \<2 mg/dL (177 μmol/L) * Life expectancy ≥ 6 months * A negative serum or urine pregnancy test before treatment must be available for both premenopausal women and for women who have \<2 years after the onset of menopause. * Informed consent
Exclusion criteria
* NHL subtypes other than OAML * Primary conjunctival OAML, unilateral involved (T1N0M0) * Ann Arbor stage III or IV * CNS involvement by the lymphoma or any evidence of spinal cord compression. Brain CT/MRI is only mandatory (within 4 weeks) with clinical suspicion of CNS involvement by the lymphoma * Pregnant or lactating women, women of child-bearing potential not using adequate contraception * Inadequate liver function tests: i. Transaminase (AST/ALT) ≥3 times the upper normal value or ii. Bilirubin ≥2 times the upper normal value * Inadequate renal function: i. serum creatinine level \<2 mg/dL (177 μmol/L) * Other serious illness or medical conditions i. Unstable cardiac disease despite treatment; myocardial infarction within 6 months prior to study entry ii. History of significant neurological or psychiatric disorders including dementia or seizures * Active uncontrolled infection (HIV, hepatitis B, Hepatitis C, active Tuberculosis, active bacterial, or active fungal infection) * Any other malignancies within the past 5 years except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix uteri * Known hypersensitivity to any of the study drugs or its ingredients (i.e., hypersensitivity to Polysorbate 20, CHO cell products, or recombinant human antibodies) * Concomitant administration of any other experimental drug under investigation or concomitant chemotherapy, hormonal therapy, or immunotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| complete response rate | 3 years | CR rate |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 5 years | Progression free survival |
| Overall survival | 5 years | Overall survival |
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | 5 years | Number of Participants with Adverse Events as a Measure of Safety and Tolerability |
Countries
South Korea
Outcome results
None listed